G. Galffy

Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

J. Jassem, T. Ciuleanu, T. Čufer, 2019, The oncologist.

Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

J. Jassem, T. Ciuleanu, T. Čufer, 2019, The oncologist.

Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Immunotherapy Show Distinct Microbial Signatures and Metabolic Pathways According to Clinical Outcomes

Z. Lohinai, G. Weiss, B. Dome, 2022, medRxiv.

Size distribution and relationship of airborne SARS-CoV-2 RNA to indoor aerosol in hospital ward environments

V. Groma, J. Osán, Á. Farkas, 2023, Scientific Reports.

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

B. Cho, R. Hauke, I. Lugowska, 2023, ESMO open.

Severe exacerbations and mortality in COPD patients: A retrospective analysis of the database of the Hungarian National Health Insurance Fund.

G. Galffy, G. Tomisa, T. Balázs, 2022, Pulmonology.